2 active not recruiting, 1 completed, 1 recruiting, 1 unknown. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Thyroid cancer, follicular: new trials by email Literature Review of Thyroid cancer, follicular trials Research Report on Thyroid cancer, follicular
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment Score (RTAS) Observations on clinicopathological factors influencing the assessment score of surgery - Thyroid Cancer, Thyroid Nodule | Recruiting | Shanghai 6th People's Hospital | 200 | 2024-12-12 | 2026-05-07 | |
| European Multicenter Study on Surgical Management of Advanced Thyroid Cancer Thyroidectomy with or without lymphadenectomy or multivisceral resection - Thyroid Carcinoma, Thyroid Cancer | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 3917 | 2022-12-15 | 2023-04-04 | |
| PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer Trametinib, Dabrafenib, PDR001 - Thyroid Cancer, Thyroid Cancer, Follicular | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 19 | 2020-09-02 | 2026-09-17 |
| Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers I-124 PET/CT lesion dosimetry, Vemurafenib, Copanlisib - Thyroid Carcinoma, Thyroid Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 8 | 2020-06-26 | 2025-09-08 |
| A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy Cabozantinib, Placebo - Differentiated Thyroid Cancer | Phase 3 | Active not recruiting | Exelixis | 187 | 2018-10-05 | 2026-10-20 |
Thyroid Cancer, Papillary (5) · Thyroid Neoplasms (5) · Adenocarcinoma, Follicular (2) · Adenoma, Oxyphilic (1) · Carcinoma, Medullary (1) · Thyroid Carcinoma, Anaplastic (1) · Thyroid Diseases (1) · Thyroid Nodule (1) · Thyroid cancer, Hurthle cell (1)
Adenocarcinoma (5) · Adenocarcinoma, Papillary (5) · Carcinoma (5) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Head and Neck Neoplasms (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Glandular and Epithelial (5) · Thyroid Diseases (4) · Adenoma (1) · Carcinoma, Neuroendocrine (1) · Neoplasms, Ductal, Lobular, and Medullary (1) · Neoplasms, Germ Cell and Embryonal (1)
Lymph Node Excision (1) · Thyroidectomy (1) · Vemurafenib (1) · cabozantinib (1) · copanlisib (1) · dabrafenib (1) · spartalizumab (1) · trametinib (1)
Memorial Sloan Kettering Cancer Center (2) · Exelixis (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Shanghai 6th People's Hospital (1)
United States (3) · Italy (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · China (1) · Croatia (1) · Czechia (1) · France (1) · Germany (1) · Hong Kong (1) · Hungary (1)
Alan L Ho, MD, PhD (2) · Ling Zhan, Doctor (1) · Marco Raffaelli, Prof (1)